Virbac acquires Thyronorm, an innovative treatment for feline hyperthyroidism, to enhance its product portfolio and address the urgent needs of senior cats.

Information on the Target

Virbac has announced the acquisition of Thyronorm, an innovative medication developed by Norbrook, specifically aimed at treating feline hyperthyroidism. This condition affects more than 10% of senior cats, leading to significant health challenges due to overproduction of thyroid hormones. The medication serves to stabilize the condition, providing a substantial improvement in the quality of life for affected pets.

Thyronorm, which has been on the market since 2016, is available in a liquid formulation, making it easier for veterinarians and pet owners to administer compared to traditional tablets. This acquisition, valued at approximately £100 million, is projected to positively impact Virbac's sales growth and EBITDA margin from the first year onwards, reflecting Virbac’s strategic approach to enhancing their product offerings in the pet health sector.

Industry Overview in the United Kingdom

The veterinary pharmaceutical industry in the United Kingdom is characterized by a growing demand for specialized treatments, particularly for chronic conditions in pets. As pet owne